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MACROPHAGE INFILTRATION IN THE AORTIC ROOTS IN MOUSE MODELS 
OF LUPUS AND ATHEROSCLEROSIS:  
THE ROLE OF INTERFERON REGULATORY FACTOR 5 
 
LING-LING LOK 
 
Abstract 
The pathogenesis of systemic lupus erythematosus (SLE) and 
cardiovascular disease (CVD) are tightly linked, and CVD is one of the leading 
causes of death in lupus patients. There are many risk factors that increase the 
risk of CVD in SLE patients, including endothelial dysfunction, lipid dysregulation, 
and abnormal regulation of innate and adaptive immunity. We have previously 
investigated the role of interferon regulatory factor 5 (Irf5), on atherosclerosis in 
lupus mouse models. Irf5 has a pro-inflammatory function by activating 
macrophage and cytokine recruitment and is thus being considered as a potential 
therapeutic target for the treatment of SLE. We hypothesized that Irf5 deficiency 
would ameliorate lupus disease as well as improve cardiovascular disease in the 
Irf5-deficient mouse model. However, while lupus disease did improve in the 
mouse model, the atherosclerotic plaques were found to be significantly 
increased in size. This poses a challenge to our current understanding of Irf5, as 
well as adds complexity to an already difficult clinical problem. Therefore, our aim 
of this study is to characterize the cells within the atherosclerotic lesions to 
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examine their inflammatory potential. The focus of this study is the infiltration of 
macrophages into the mouse aortic root as determined by immunohistochemistry 
staining. 
In a time-course study using apoE.Irf5-/- mice, we found that macrophages 
started to accumulate into aortic leaflets as early as two weeks after starting a 
Western diet. Macrophage infiltration into the site of leaflet attachment seemed to 
possibly be a precursor to atherosclerotic lesion formation and appeared as early 
as 4 weeks after starting Western diet. No apparent differences were found 
between Irf5 sufficient and Irf5 deficient mice at either two or four weeks on 
Western diet. 
In a bone marrow chimera study, we examined the effects of Irf5 from 
bone marrow- and non-bone marrow-derived cells on the accumulation of 
macrophages on aortic leaflets and in the tunica intima in the gld.apoE-/- mouse 
model of lupus and atherosclerosis. Macrophage accumulation did not correlate 
with differences in Irf5 production. However, the finding of macrophage 
accumulation on aortic leaflets suggests a role of macrophages in Libman-Sacks 
endocarditis, an inflammatory disease of the mitral and aortic valves seen in 
patients with lupus.  
Together, our results do not support nor refute a role of Irf5 in macrophage 
infiltration into the aortic root. More samples are needed, as are more methods of 
identifying macrophages and quantifying them. However, it is still likely that 
vii 
 
macrophages play a role in the pathogenesis of atherosclerotic lesion formation 
in a lupus mouse model, and it is an area of study worth exploring.  
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INTRODUCTION 
Epidemiology 
Lupus is a chronic, systemic autoimmune disease that is characterized by 
flares that can cause damage to potentially any organ in the body1. Systemic 
lupus erythematosus (SLE) is the most common and most serious form of lupus2 
and is the focus of this study. Other forms of lupus include discoid or cutaneous 
lupus, which does not affect any of the body’s internal organs, and drug-induced 
and neonatal lupus, which usually do not cause permanent damage after 
treatment3. From this point forward, the type of lupus discussed here will be 
systemic lupus erythematosus, and the terms “lupus” and “SLE” will be used 
interchangeably.  
The pathogenesis of SLE culminates from the formation of autoantibodies 
in the patient, which is the result of a loss of self-tolerance. Immune complexes, 
comprised of autoantibody bound to autoantigen, then form and deposit in 
various organs and cause damage by triggering an immune response that leads 
to the influx of type I interferon (IFN) and other inflammatory modulators. As a 
systemic disease, the damage can occur in any organ, including the kidneys, 
skin, heart, lungs, intestine, and brain.  
According to the Lupus Foundation of America, approximately 1.5 million 
Americans have lupus, with 16,000 new cases reported each year and an 
estimated 5 million people are affected worldwide1. Despite its prevalence, SLE 
remains a mysterious disease; there is no known cure, the disease course is 
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unpredictable, and even the diagnosis can be difficult. The symptoms that 
manifest among lupus patients vary so widely that lupus is known as the “disease 
of a thousand faces,”2 and the American College of Rheumatology deemed it 
necessary to create a set of diagnostic criteria to facilitate the proper 
classification of SLE3. In spite of these obstacles, treatment options have 
improved in recent years and patients can now expect a 95% survival rate for 5 
years, a 90% survival rate after 10 years3, and a 78% survival rate at 20 years4. 
This is an improvement from even as recently as 2009, when lupus survival rates 
were reported to be 90% at 5 years and 80% at 10 years5. 
Etiology and Risk Factors 
The etiology of lupus involves both environmental triggers as well as 
genetic susceptibility. Though people of all genders, ages, and ethnic groups are 
susceptible, there are some risk factors that put certain populations at a higher 
chance of developing the disease. Nearly ninety percent of SLE patients are 
women of child-bearing years, and the highest prevalence is in African-American 
and Afro-Caribbean women4. Environmental triggers, such as ultraviolet (uv) light 
or viral infection, may activate epigenetic changes in susceptible individuals, 
resulting in abnormal immune responses.  
SLE has a moderately strong genetic component, as evidenced by 
reported 40% concordance rates among monozygotic twins, compared to 4% 
among dizygotic twins6. A mother with lupus passes on a 1:40 risk of lupus in her 
daughter and a 1:250 risk in her son7. SLE is in fact a multigenic disease that 
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activates in a threshold-like manner when a genetically susceptible individual has 
polymorphisms of multiple genes that each contribute to an aberrant immune 
response. Many of these genetic factors are genetic polymorphisms associated 
with interferon-α (IFN- α), such as the signaling molecule interferon regulatory 
factor 5 (Irf5), which will be discussed further in Chapter 1. Genes involved in 
clearance of apoptotic debris or immune complexes, are also implicated, as are 
genes that influence DNA (deoxyribonucleic acid) repair4.  
SLE affects women at a higher frequency than men, with an 8:1 ratio. 
Several factors may be responsible, such as hormonal effects, and genes on the 
X chromosome. Females tend to have a more active and a more prolonged 
immune response. For example, females of many mammalian species have an 
increased antibody response. Estradiol is also shown to lengthen the immune 
response by increasing the activation and survival of T and B lymphocytes, and 
women undergoing hormone replacement therapy or using oral contraceptives 
have a 1.2-2 fold increase in SLE susceptibility4. The role of the X chromosome 
on the development of lupus is supported by the fact that the frequency of 
Klinefelter’s syndrome (47,XXY) is found at a higher frequency (14-fold) among 
men with SLE than men without SLE. This risk is predicted to be similar to the 
risk of normal 46,XX women and thus suggests that the risk of developing SLE is 
partly due to a gene-dose effect from the X chromosome8. 
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The environment plays a significant role in lupus development by 
providing precipitating factors or “triggers” that cause the onset of a flare. Such 
triggers include ultraviolet light, infections, and smoking7. Ultraviolet light has the 
ability to alter DNA and intracellular proteins to make them antigenic, as well as 
the ability to increase apoptosis in the patient’s skin cells4. These processes 
cause flares in patients, likely due to a decreased response in clearance of 
immune complexes and apoptotic cells. Viral infections are known to trigger 
lupus flares, as the activation of the immune response often leads to the 
formation of autoantibodies due to the patient’s loss of self-tolerance and/or 
decrease in immune cell regulation. In particular, Epstein-Barr virus (EBV) has 
been suggested to play a role as a lupus trigger, as adult SLE is strongly 
associated with previous EBV exposure9. It is possible that SLE predispositions 
may lead to EBV deregulation, which in turn initiates a flare in the susceptible 
individual. The proposed mechanism involves the aberrant expression of viral 
latent and lytic genes in the blood of SLE patients, which leads to a perturbed 
response to EBV infection and an increased viral load. The underlying host 
immune cell dysfunction is suggested to contribute to EBV persistence, which 
may influence changes in B cell behavior or regulation that lead to autoantibody 
production10. Finally, another major environmental stimulus that affects SLE is 
tobacco smoking, which increases risk of lupus at an odds ratio of 1.54. This will 
be explored later in further detail.  
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Atherosclerosis and Lupus Risk Factors 
SLE is a condition tightly linked to cardiovascular disease (CVD), causing 
significant morbidity in the lupus patient population. Mortality in lupus patients 
follows a bimodal curve, with a pronounced spike in deaths caused early by 
acute organ failure and infections, followed later in life by another peak that is 
caused mainly by cardiovascular disease11. Despite improvements in 10-year 
survival, lupus patients still suffer from an increased risk for CVD compared to 
the general population12.  There is some evidence that reports a 50 fold increase 
in risk for cardiovascular disease in lupus patients compared to the general 
population13, according to reports with age-matched controls from the 
Framingham offspring study14. Atherosclerosis was once thought to be caused by 
an increase in patient age, but it is now a widely accepted belief that 
atherosclerosis is a condition of chronic inflammation in the vessel wall15. Due to 
this inflammatory nature, there is reason to investigate the possible connection 
between the high autoimmune activity in SLE and increased incidence of CVD in 
SLE patients12. In fact, there is extensive literature on the risk factors and 
pathological mechanisms that these two conditions share. 
Current modifiable risk factors for cardiovascular disease include smoking 
and metabolic syndrome12, both of which are also factors that increase risk of 
triggering autoimmune responses, or that are found with higher prevalence in 
SLE patients. Proposed mechanisms for this linkage include endothelial 
dysfunction, lipid dysregulation, and irregular system function, such as IFN over-
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activation. In addition, dysregulated adaptive immunity points to a link between 
atherosclerosis and SLE through the diminished function of regulatory T cells and 
through the role of autoantibodies in both diseases12.  
 This section will go over in detail the risk factors and proposed 
mechanisms that atherosclerosis and lupus both share. Included in this 
discussion are traditional CVD risk factors, which are composed of modifiable 
and non-modifiable risk factors, and novel CVD risk factors which are those that 
cannot be explained by the traditional Framingham risk factors alone.  
i) Traditional CVD Risk Factors 
 According to the American Heart Association, tobacco smoke, high blood 
pressure, and insulin resistance account for three of the 6 major independent 
modifiable factors for coronary heart disease16, all three of which have possible 
mechanistic similarities to lupus pathogenesis.  According to Surgeon General 
Report of 201017, smoking-related CVD is responsible for 140,000 premature 
deaths annually, and smoking accounted for 33 percent of all deaths from CVD 
and 20 percent of deaths from ischemic heart disease in people 35 years of age 
and older. In autoimmune disorders, including SLE, tobacco smoke is also known 
to be a trigger of autoimmune responses12. In fact, smoking increases the risk of 
developing SLE symptoms in a lupus patient by 50 percent4, 18, possibly by 
promoting the presentation of hidden epitopes and triggering epigenetic 
modification of self-antigens. In smoking, the mechanism responsible includes 
the induction of a hypercoagulable state which, together with the narrowing of the 
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vascular lumen from atherosclerotic changes, creates a risk of acute thrombosis. 
This mechanism is mirrored in the pathogenesis of cardiovascular disease in 
lupus, which could also be linked to a hypercoagulable state. In lupus patients, 
lupus anticoagulants and anticardiolipin antibodies are seen 34% and 44% of the 
time respectively, and are considered to be an acquired condition that is 
associated with venous thromboembolic events and arterial thrombosis19. While 
these antibodies seem to contribute to the hypercoagulable state like the 
traditional risk factor of smoking, they are considered a non-traditional 
Framingham risk factor and will be discussed later on the topic of autoantibodies. 
 As discussed in the 2015 Benvenuti review, metabolic syndrome, which 
includes insulin resistance, hypertension and dyslipidemia, also contributes to the 
increased risk of developing atherosclerosis in a lupus patient. In fact, CVD was 
twice as prevalent among SLE patients with metabolic syndrome as their age- 
and sex-matched controls without metabolic syndrome. Insulin resistance is 
correlated with subclinical damage in SLE patients, which may be related to the 
increased susceptibility of lupus patients to develop insulin resistance. This 
increased risk of developing insulin resistance is tied to the development of 
dyslipidemia and hyperglycemia, which may be due to insufficient physical 
activity, extensive corticosteroid use, and chronic systemic inflammation. These 
components of metabolic syndrome worsen the prognosis in affected SLE 
patients by increasing the activity index score of SLE (SLEDAI) and exhibiting 
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more severe kidney disease compared to SLE patients without metabolic 
syndrome12.  
 Also discussed is the non-modifiable traditional risk factor of ethnicity that 
may put SLE patients at a higher risk for developing cardiovascular disease. 
African American women are at a 3-4 fold higher risk of developing SLE than 
their Caucasian counterparts20, and also appear to have more severe clinical 
manifestations12. This worsened prognosis due to racial factors is also seen in 
lupus patients with regards to the development of cardiovascular disease. SLE 
patients of African descent were not only hospitalized for CVD at an earlier age 
by about 10 years, but they also died of CVD 13-14 years younger than their 
Caucasian counterparts12.  
ii) Non-Traditional CVD Risk Factors 
Increased risk of CVD in lupus patients cannot be entirely explained by 
traditional Framingham risk factors. Proposed mechanisms for this increase in 
risk include factors related to lupus pathogenesis as well as treatment-related 
risk factors.  
Endothelial dysfunction plays an important role in atherogenesis, and 
endothelium-dependent vasodilation has been seen to even predict adverse 
cardiovascular events and long-term outcome21. Endothelial cells have an 
important role in nitric oxide production, and changes in production can result in 
the oxidation of lipoprotein particles that bind to matrix macromolecules. These 
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oxidized lipoproteins in turn have a pathogenic role in the development of 
atherosclerosis from an increased accumulation of oxidation products, which 
cause the breakdown of fatty acids and phospholipids whose products can 
stimulate local inflammation22. Lupus patients with active disease are proposed 
to have a predisposition for initiating this process of atherogenesis, due to the 
high level of endothelial inflammatory biomarkers which include vascular cell 
adhesion molecule, vascular endothelial growth factor, von Willebrand factor, and 
E-selectin. 
Lipid dysregulation, in the forms of hyperlipidemia and dyslipidemia, are 
also major contributing factors for the development of CVD23. Commonly found in 
lupus patients, these factors may be caused by disease-related mechanisms, 
such as how low density lipoproteins (LDLs) and very-low density lipoproteins 
(VLDLs) can be caused by nephrotic syndrome, or by treatment-related 
mechanisms, such as increased levels of LDLs caused by extended 
corticosteroid usage12. 
Innate and adaptive immunity also play a role in increasing risk of CVD in 
SLE. For example, the IFN signature that is characteristic of many SLE patients 
leads to dysfunction of endothelial cells and stimulation of inflammasome 
expression. Also, the depletion of regulatory T cells seems to be related to SLE 
disease severity, anti-dsDNA (double-stranded DNA) production, and kidney 
involvement as well as the development of atherosclerosis12.   
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Autoantibodies are the most characteristic attribute of lupus, and their 
many types are associated with atherosclerosis progression and CVD. Anti-
dsDNA antibodies are associated with more severe CVD, antiphospholipid 
antibodies were tound to be strongly associated with arterial and venous 
thrombosis, and were also proposed to contribute to atherosclerotic plaque 
formation by facilitating leukocyte infiltration into the tunica intima.  
Pathogenesis 
i) Lupus Pathogenesis 
As previously discussed, SLE patients experience an aberrant immune 
response due to environmental triggers combined with genetic susceptibility. 
These abnormal immune responses can emerge as either aberrant innate 
immunity or in adaptive immunity. In the innate immune response, dendritic cells 
or monocytes and macrophages can be improperly activated by various antigens, 
such as DNA and RNA (ribonucleic acid) presented as immune complexes or 
from the viral genome. In adaptive immunity, self-tolerance can be lost or 
activation thresholds can be lowered during the development of T and B 
lymphocytes. There can also be a disrupted regulatory system that is caused by 
ineffective CD4+ and CD8+ T cells, B cells, and myeloid-derived suppressor 
cells. Finally, inadequate clearance of apoptotic cells or antigen complexes can 
contribute to an accumulation of debris that triggers immune cell4.  
This immune response involves increased expression of pro-inflammatory 
type 1 and 2 interferons (IFN), which induce a pattern of gene expression that 
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appears in the peripheral blood cells of 50-60% of lupus patients4. Other factors 
and cytokines are secreted, such as tumor necrosis α (TNF-α), and IL-17. 
However, there is also a decrease of cytokines that are normally responsible for 
maintaining regulatory CD4+ and CD8+ T cells. This is due to the insufficient 
amount of IL-2 and TGF-B produced by T and NK cells, and results in the 
production, accumulation, and persistence of autoantibodies and immune 
complexes.  
Upon stimulation of the immune system, multiple tissues such as 
endothelial cells or tissue-fixed macrophages become activated and facilitate 
entry of B and T leukocytes into target tissues. Sustained production of 
autoantibodies and the influx of inflammatory mediators create a chronic state of 
inflammation that results in tissue damage that can cause irreversible scarring4. 
ii) Atherogenesis  
A particular point of interest is the formation of atherosclerotic lesions and 
the progression of plaque development and plaque rupture. Gaining insight into 
the process of lesion development is crucial to the prevention of life-threatening 
thrombosis as well as the understanding of the link between atherosclerosis and 
SLE. A better understanding of the pathogenesis of CVD in lupus will provide 
insight into better therapeutic targets by addressing the pathogenic mechanisms 
that they both share. Our current understanding of plaque formation involves lipid 
deposition into the endothelial wall, in particular from low-density lipoprotein. 
These lipoproteins accumulate and bind to the extracellular matrix and often 
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undergo oxidative modification. Oxidative modification results in the formation of 
oxidation products which in turn triggers an inflammatory response that will set 
into motion the steps of lesion formation22.  
The first stage of atheroma formation involves leukocyte recruitment, with 
preferential accumulation of macrophages, dendritic cells, T and B lymphocytes, 
and mast cells. This process can be enhanced by the presence of pro-
inflammatory cytokines, such as interleukin-1 (IL-1) and TNF, by increasing the 
expression of leukocyte adhesion molecules and further inflammatory cell 
migration into the intima. Upon diapedesis, monocytes will mature into 
macrophages and take up the lipoproteins present, thus becoming lipid-laden 
“foam cells”. This formation of foam cells completes the process of forming the 
fatty streak, which is the precursor to the atherosclerotic plaque22.  
While the fatty streak does not necessarily cause the formation of a 
plaque, the presence of fatty macrophages is a required stage that precedes the 
development of the necrotic core. This necrotic core forms as a result of the 
eventual death of the macrophage foam cells, which leave behind the lipids as a 
dense accumulation in the center of the lesion. This process is exacerbated by 
impaired foam cell clearance, and the state of the lesion may be further 
complicated by the cytokines and factors released by the dying foam cells22.  
In a separate but related process, the extracellular matrix is capable of 
forming fibrous tissue that characterizes the fibrofatty lesion. This type of fibrous 
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plaque is more clinically significant, due to its potential to contribute to 
hemodynamic stenosis and to plaque instability. Smooth-muscle cells contribute 
to fibrosis by proliferating and stimulating production of extracellular matrix within 
the lesion. Smooth-muscle cells themselves also form a part of the necrotic core 
upon apoptosis, in the same way that macrophages do22.  
At the height of plaque instability, the lesion reaches a critical point before 
rupturing and thereby inducing thrombus formation which in turn has the potential 
to result in a fatal occlusion of the vessel lumen. Factors that heighten the risk of 
lesion rupture include the presence of inflammatory mediators such as IFN-y, a 
high density of macrophages, large lipid cores, and thin fibrous caps, which 
account for a weak and vulnerable plaque22.  
Given our current understanding of atherogenesis, the importance of 
macrophage migration and maturation to the development of the atherosclerotic 
plaque is clear. However, the characterization of the macrophages within the 
lesion is still incomplete; the roles of the macrophages have been proposed to be 
both patrolling and/or inflammatory. It is still unclear whether or not there are 
multiple cell types at work, or if they are all indeed of a monocyte origin and are 
merely specialized forms of the same cell. 
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CHAPTER ONE: The Role of Irf5 in Macrophage Infiltration in the ApoE-/- Mouse-
Model of Atherosclerosis; a Time-Course Experiment 
IRF5 Proposed Mechanism 
Toll-like receptor (TLR) signaling is known to play a role in the production 
of inflammatory cytokines through the activation of interferon regulatory factor 5 
(Irf5), a transcription factor. Irf5 is also linked to signaling in apoptotic pathways, 
promoting helper T cell responses, and polarizing macrophages to an 
inflammatory phenotype24. This is consistent with the finding that Irf5 
polymorphisms have a strong association with increased risk of various 
autoimmune disorders, including SLE.  
As a result, Irf5 is being considered as a potential therapeutic target for 
the treatment of SLE. Previously in the generalized lymphoproliferative disease 
(gld) and apolipoprotein E (apoE) deficient (gld.apoE-/-) mouse model of 
atherosclerosis and lupus, we had found that Irf5 deficient mice had ameliorated 
lupus disease compared to their Irf5 sufficient gld.apoE-/- counterparts, which 
supports the proposal that Irf5 plays a pathogenic role in the pathogenesis of 
lupus. However, we made the unexpected finding that Irf5 deficient gld.apoE-/- 
mice also exhibit an increase in severity of atherosclerosis, as seen in the 
increased lesion size25. This was an unexpected result as we had predicted that 
decreased Irf5 expression would reduce inflammation and therefore reduce 
atherosclerosis. Therefore, our current plan is to characterize the cell types 
contributing to the formation of the lesion, with a focus on macrophage infiltration. 
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Our aim is to determine if the increase in lesion size found in the Irf5 deficient 
gld.apoE-/- mice is correlated with an increase in inflammatory severity as seen 
by an increase in macrophage accumulation on aortic root leaflets. In addition, 
we want to determine whether Irf5 deficiency increases atherosclerosis in a 
mouse model of atherosclerosis without lupus, the apoE-/- model. It has been 
shown that macrophages will infiltrate the subendothelial space in apoE-/- mice 
after being on Western diet for as little as 5 weeks26. By using a time-course 
study design, we will aim to pinpoint the amount of time on Western diet after 
which macrophage will begin to accumulate in the aortic root. We will also aim to 
determine if Irf5 deficiency will delay macrophage infiltration due to dampening its 
inflammatory effects on macrophages, or if Irf5 deficiency will exacerbate lesion 
formation, as seen previously in gld.apoE-/- mice in Watkins et al. 2015. 
Materials and Methods 
Mice 
All mice used were apoE deficient, and the experimental condition was Irf5 
deficiency. Mice were fed Western diet starting from 7 weeks of age. 
i) IRF5 -/- 
As a continuation of the 2015 Watkins et al. paper, this study examined 
the role of macrophages in atherosclerotic lesions in a lupus mouse model. Thus, 
Irf5-/- mice of the same lineage as the gld.Irf5-/- mice in the 2015 Watkins et al. 
paper were used. Irf5-/- mice were obtained from T. Taniguchi (University of 
Tokyo, Tokyo, Japan) and T. Mak (University of Toronto, Toronto, Ontario, 
Canada) (Tanaoka et al. 2005). In the immune cells of Irf5-/- lupus-prone gld-/-
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mice, TLR signaling downstream of MyD88 (myeloid differentiation primary 
response gene 88) is severely impaired. As a result, several pro-inflammatory 
cytokines including interleukin-6 (IL-6), IL-12, and TNF-α are markedly decreased 
in the serum27. Irf5 deficient mice show resistance to lethal doses of 
unmethylated DNA and have been shown to develop less severe disease in 
multiple mouse models of SLE24. Our aim is to elucidate the inflammatory role of 
Irf5 in a non-lupus-prone mouse model. 
ii) ApoE -/- 
ApoE deficient mice are a strain of mice that show increased susceptibility 
to cardiovascular disease when fed a high-fat diet. This condition of high-risk in 
atherosclerosis is due to the deletion in the apoE gene. apoE (apolipoprotein E) 
is a class of apolipoprotein that is typically found in chylomicrons and 
intermediate-density lipoproteins (IDLs) and allow for the catabolism of 
triglyceride-rich lipoproteins. If this catabolic pathway is impaired, lipoproteins are 
more likely to accumulate within the endothelial wall and thus begin the formation 
of the fatty streak. ApoE deficient (apoE-/-) mice show signs of 
hypercholesterolemia and atherosclerosis, and this phenotype is more quickly 
expressed when fed a “Western diet”. 
Western Diet 
Western diet was used in the time-course study for 2 or 4 weeks to 
accelerate atherogenesis. The Western diet contained 21% fat (with anhydrous 
milk fat as the source), and 0.2% cholesterol. This diet’s saturated fatty acids 
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make up over 60% of the total fatty acids, is 34% sucrose by weight28, and was 
purchased from Harlan Teklad (catalogue number TD 88137).  
F4/80 Staining 
According to Hume et al in 1983, F4/80 was initially identified from a 
hybridoma that secretes a rat IgG2b specific for a plasma membrane antigen of 
mouse mononuclear phagocytes29. They reported that F4/80 is a maturation 
marker for mononuclear phagocytes in liquid bone marrow cultures, and is 
exclusively expressed in monocytes and splenic dendritic cells29. The F4/80 
marker has since been commonly used as a macrophage cell surface marker.  
Perfusion/Embedding/Sectioning 
 After the designated time on Western diet, the animal was sacrificed and 
the heart and spleen were taken out for embedding. This was done by the CO2 
method of euthanasia, then by opening the body cavity, cutting the caudal vena 
cava and perfusion of 10mL of PBS through the l ventricle. The heart was cut at 
a 45-degree angle to remove the excess tissue below the atria. For 
cryoprotection, the tissue was submerged in 15% and 30% sucrose until the 
tissue became isotonic with the solution and sank. The tissue was lightly dried on 
paper towels, then the cut side of the heart tissue was placed down into a 
cartridge filled with OCT Compound (Tissue-tek, catalogue no. 4583) before 
submerging in methylbutane chilled by dry ice. The spleen was also submerged 
in the same sucrose solutions, dried, embedded in OCT Compound and snap-
frozen in methylbutane.  
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 Sectioning was done at a cryostat, cutting 8µm-thick sections onto 
positively-charged Superfrost Slides (Fisher Scientific, catalogue no. 12-550-15). 
Optimal cutting temperature for the aortic roots were at -20°C to -24°C and the 
optimal cutting temperature for the spleen was -14°C. Following mounting, tissue 
slides were dried for 15 minutes then stored in the -20°C or -80°C freezer.  
Staining IHC 
 Tissues were stained with immunohistochemistry (IHC) for macrophage 
marker F4/80 (AbD Serotec, catalogue no. MCA497R). Slides were taken from 
freezer storage, dried for 10-20 minutes, and then further dehydrated in acetone 
for 6-10 minutes to fix the tissue to the slide. Slides were rinsed in PBS and then 
tissues were circled with hydrophobic marker. Tissue was rehydrated with Bloxall 
Blocking Solution (Vector Laboratories, catalogue no. SP-6000) for 15 minutes 
before being blocked with 4% normal goat serum (NGS) blocking solution for 1 
hour in a humidified chamber. Blocking solution was suctioned off with a vacuum-
pipette system, and then the primary antibody was placed directly on the tissue 
with no prior wash.  
 The antibody used was monoclonal IgG2b rat anti-F4/80 at a 
concentration of 1:800 (original concentration 1.0mg/ml) and was diluted in 10% 
NGS. As a control for F4/80, an IgG2b isotype control (R&D Systems, catalogue 
no. MAB0061) was used at the same concentration of 1:800. Primary antibody 
was left on the tissue in a humidified chamber for 1 hour or overnight in 4°C. 
After primary antibody incubation, solutions were suctioned off prior to a PBS 
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(phosphate buffered serum)-Tween and two PBS washes. A goat anti-rat 
micropolymer HRP (horseradish peroxidase) was used as the secondary 
antibody (Vector Laboratories, catalogue no. MP-7444) and placed on the tissue 
for 30 minutes. Tissues were washed with PBS before developing. 
 Tissue developing was accomplished using the ImmPACT AMEC Red 
Peroxidase Substrate kit (Vector Laboratories, catalogue no. SK-4285). Tissues 
were placed under AMEC solution for 2-2.5 minutes and then washed with 
distilled water and PBS.  
 As a counterstain, slides were dipped in Harris hematoxylin for 40-45 
seconds then washed with running tap water. 
 Mounting the over slips was done with a VectaMount AQ aqueous 
mounting medium purchased from Vector Laboratories (catalogue no. H-5501). 
After cover-slipping, slides were sealed with nail polish. 
Quantification methods 
 Aortic roots were examined by microscope (Olympus BX41) on 4x, 10x, 
and 40x magnification. Macrophage populations were quantified on each leaflet 
by gross estimation on a 0 to ++ scale, with comparison to the isotype control of 
the primary antibody to control for non-specific background staining.   
Results 
As this is the initial study in the time-course project, we have included two 
time points that examine the macrophage accumulation in the aortic root (see 
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Figure 1 for diagram of aortic root structure). These time points are at two and 
four weeks after starting Western diet. The Western diet was started when the 
mice reached 7 weeks of age. For each time point, there was an experimental 
group (apoE.Irf5-/-) and a control group (apoE.Irf5+/+).  
At the two week time-point, relatively minimal macrophage accumulation 
was seen in either the Irf5 sufficient (Figure 2A-D) or deficient (Figure 2E-H) 
condition. There are no atherosclerotic lesions in the aortic leaflets to be seen in 
the Irf5 deficient mouse yet. A notable finding is the presence of black deposits 
that sit on the surface of the leaflet (Figure 2C). This can be found on the tissue 
before staining, at the time of sectioning the tissue with the cryostat. It is 
important to note that the black deposits appear even without primary antibody or 
the isotype control, as it is present in the PBS control slide (Figure 2C, right). 
This may be cell debris or simply foreign bodies that accumulate on the surface 
of the leaflets. 
While macrophages were not prominently seen on the leaflet themselves, 
it is interesting to observe the beginning of some macrophage activity at the inter-
leaflet triangle (Figure 2D,F; refer to Figure 1 for diagram of inter-leaflet triangle) 
and along the site of leaflet attachment (Figure 2F). Macrophage accumulation at 
the later stages of aortic root atherogenesis at 12 weeks of Western diet is very 
dense at the inter-leaflet triangle25, and it is curious to witness the beginning of 
this infiltration. This early F4/80 expression was observed nearly equally in both 
Irf5 sufficient and deficient cases. 
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At four weeks, there was the surprising finding that there was the 
appearance of an early atherosclerotic plaque beginning to form within the 
leaflet, as evidenced by the apparent increased thickness as well as macrophage 
activity at the site of leaflet attachment. According to the study in Boring et al 
1998, early macrophage infiltration occurred at 5 weeks of Western diet and we 
had not expected macrophages to be infiltrating at 2 weeks and forming 
atherosclerotic lesions at 4 weeks of Western diet. Both the Irf5 sufficient (Figure 
3A-D) and deficient (Figure 3E-H) tissues displayed signs of lesion formation and 
macrophage activity at the leaflet attachment. Some macrophage accumulation 
was seen on the leaflets. Interestingly, the inter-leaflet triangles in both 
specimens were relatively free of macrophages within the triangles, but saw 
accumulation of macrophages on the surface of the inter-leaflet triangles.  
 
  
Figure 1. A 3D cross-section of the aortic root. Shown in brown is one of 
three leaflets that connect to the aortic wall by the site of leaflet attachment, 
shown in red, dark brown, and dotted pink. Shaded in grey is the inter-leaflet 
triangle. We have found this area to be particularly prone to macrophage 
infiltration before and during the time period that macrophages can be seen 
accumulating on the leaflets themselves. (Adapted from Charitos EI, 
SieversHH 2013.
33
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Figure 2. Minimal macrophage infiltration with two weeks on Western diet. apoE.Irf5
+/+ 
mouse is 
labeled A-D, apoE.Irf5
-/-
 mouse is labeled E-H. Images A-D look different from E-F because the 
hematoxylin counterstain was unavailable at the time. Anti-F4/80 antibody staining is pictured on 
the left, and the corresponding IgG2B isotype control is pictured on the right, except in 2C where 
PBS is substituted for the isotype control. (2A) 4x magnification of Irf5 sufficient mouse. (2B) 10x 
magnification of two inter-leaflet triangles that show minimal macrophage staining. (2C) 40x 
magnification of black deposits (green arrows) of unknown origin that appear with or without 
antibody staining. (2D) 40 magnification of inter-leaflet triangle (shown in the top right of 2B) that 
shows a few cells with positive F4/80 staining (red arrows). (2E) 4x magnification of an Irf5 
deficient mouse. (2F,G,H) 40x magnification of macrophage infiltration at the inter-leaflet triangles 
and at the site of leaflet attachment that show cells with positive F4/80 macrophage staining (red 
arrows). 
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Figure 3. Atherosclerotic plaque formation seen as early as 4 weeks on Western diet. apoE.Irf5
+/+ 
mouse is labeled A-D, apoE.Irf5
-/-
 mouse is labeled E-H. Anti-F4/80 antibody staining is pictured 
on the left, and the corresponding IgG2B isotype control is pictured on the right. Positive staining 
is indicated in red arrows. (3A) 4x magnification shows two leaflets of the aortic root in the Irf5 
sufficient mouse with early accumulation of macrophages appearing near the inter-leaflet  triangle 
and along the site of leaflet attachment, where a potential atherosclerotic plaque is starting to 
form. (3B) 10x magnification that shows a closer look at the macrophage accumulation in the 
leaflet as well as in the tunica adventitia outside of the aortic root. (3C,D) 40x magnification of 
early atherosclerotic plaque formation. (3E) 4x magnification of an Irf5 deficient mouse also 
showing early plaque development. (3F, G) 40x magnification of macrophage accumulation at the 
site of leaflet attachment, possibly preceding atherogenesis. (3H) 40x magnification showing 
minimal macrophage staining on the surface of the leaflets. 
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Discussion 
According to our time-course experiment, we have found that macrophage 
infiltration into the center of the inter-leaflet triangles of the aortic root can be 
found as early as two weeks after induction of Western diet, and macrophages 
can also be found on the outer edges of the inter-leaflet triangles and on the 
leaflets as early as 4 weeks after induction of Western diet. No significant 
differences can be seen between the experimental and control condition in these 
samples.  
It is, however, interesting to note that the appearance of macrophages in 
the intima of the inter-leaflet triangles has preceded the appearance of 
macrophages on the outside, and also on the leaflets themselves. This suggests 
the possibility of macrophages migrating outwards from the inter-leaflet triangles 
to the lumen of the leaflets. The macrophages present at the earliest stages 
could be resident macrophages that are continually present in the aorta. 
However, the absence of macrophages in the inter-leaflet triangles at the time 
that they are seen on the surface of the leaflets does not support the theory of 
resident macrophages or the theory of macrophage migration as a continual 
process.  
It was surprising to observe the early stages of atherosclerotic lesion 
development as early as 4 weeks after the start of Western diet (Figure 3). With 
such an early start to the process of lesion formation, we can alter our future 
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plans for time-course points and narrow down the window during which 
inflammation begins to occur at the leaflet connection site. Ideally we will have a 
time-point at 3 weeks, and possibly time-points in the middle of weeks as well.  
It was also encouraging to see defined cell F4/80 staining on the 
membrane of the macrophages at the base of the leaflet, as in our previous 
experience with older mice on Western diet for a longer duration, the 
atherosclerotic lesion does not show clearly-delineated cells, with or without 
F4/80 marker. This lack of clear cell delineation may either be due to the 
differentiation of macrophages to foam cells, possibly causing them to lose 
expression of F4/80, or due to the apoptosis of the cells altogether as a part of 
the development of the necrotic core. Further time points with a longer duration 
of Western diet will be needed to investigate this question and elucidate the time 
frame within which this change in macrophage surface antigen expression 
contributes to the formation of an atherosclerotic lesion. 
The largest drawback to this study is the insufficient number of n. We 
currently have data for two time points, with an n = 1 in each category. Future 
goals will include increasing this number to at least n = 4 in each condition, as 
well as increasing the number of time points of varying duration of Western diet. 
Future studies will also need to control for gender differences and littermates. 
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Macrophage classification should also be expanded in future studies to 
include Mac3 staining as to confirm the presence of macrophages within the 
leaflets, the inter-leaflet triangles, and the atherosclerotic lesions.  
In addition, it will be important to look at macrophage function as well as 
macrophage number. This could be done using gene expression analysis of the 
atherosclerotic lesions or staining of the macrophages for cytokine protein 
expression. It is also of interest to investigate the presence of other immune cell 
types in the lesion such as B and T lymphocytes and dendritic cells. 
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CHAPTER TWO: The Impact of Bone Marrow-Derived and Non-Bone Marrow-
Derived Irf5 on Macrophage Accumulation in the Aortic Roots of the 
gld.apoE-/- Mouse Model 
Introduction: Bone Marrow Chimeras 
In the same 2015 Watkins paper that showed exacerbated atherosclerosis 
in Irf5 deficient mice, it was shown that there are different effects of Irf5 
deficiency, dependent on if the Irf5 deficiency was in bone marrow-derived cells 
or non-bone marrow-derived cells. To investigate this matter, bone marrow 
chimera studies were done by irradiating Irf5 +/+.gldapoE-/- and Irf5 -/-.gldapoE-/- 
“recipient” mice and reconstituting the irradiated mice with bone marrow from 
Irf5+/+.gldapoE-/- or Irf5 -/-.gldapoE-/- age-matched “donor” mice.  
It was found that the development of autoimmune disease was primarily 
dependent on Irf5 expression in bone marrow-derived cells, as mice that 
received Irf5 sufficient bone marrow developed splenomegaly, lymphadenopathy, 
and high-titer ANAs compared to their Irf5 deficient bone marrow counterparts. 
Atherosclerotic lesion size was also measured in the bone marrow 
chimeras, and it was not only confirmed that Irf5 deficiency promotes 
atherosclerosis, but also found that both the bone marrow-derived and the non-
bone marrow-derived cell populations contributed to the effect of increased 
atherosclerosis. Irf5 deficiency in the recipients resulted in a more statistically 
significant contribution to increased lesion size compared to Irf5 deficiency in the 
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donor mice, but the largest atherosclerotic lesions were found in the mice with 
Irf5 deficiency in both the donor and recipient, suggesting that the effects of Irf5 
expression in the bone marrow-derived cells and the non-bone marrow-derived 
cells is additive. 
The goal of this current project was to extend these results by correlating 
atherosclerotic lesion size with macrophage deposition on the leaflets of the 
aortic root by using immunohistochemistry to stain with the F4/80 marker. 
Materials and Methods 
i) gld-mice 
 An important cell type involved in the pathogenesis of autoimmunity is the 
T lymphocyte, which itself has several subtypes. The normal role of the cytotoxic 
T cell is to kill infected target cells, and the role of the T helper cell is to activate B 
lymphocytes to produce antibodies and to activate cytotoxic T cells to eliminate 
harmful cells. In a healthy individual, lymphocytes mature under strict 
surveillance in order to dispose of self-reactive cells that would otherwise target 
the host’s own healthy cells for immune-mediated destruction. In autoimmune 
disorders, however, this “surveillance” system, known as self-tolerance, breaks 
down and autoantibodies are generated.  
A proposed mechanism suggests that overactive T cells can produce 
nonspecific signals which in turn lead to increased B lymphocyte activation by 
circumventing the antigen-specific selective role of T helper cells. This 
unmonitored B cell activation leads to the formation of autoantibodies and thus 
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the formation of immune complexes in seen in diseases like SLE30. The model 
used in this study takes advantage of this mechanism in order to mimic SLE in 
mice. The model selected is the gld-mutated mouse model, which has a defect in 
the gene that codes for Fas ligand (FasL). FasL is a well-established cell surface 
molecule that triggers apoptosis in lymphocytes31. In gld-mutated mice, defects in 
T-cell-mediated apoptosis is seen, and a lupus-like phenotype can be observed 
in the mice. In particular, the production of low levels of autoantibodies, mild 
splenomegaly, lymphadenopathy, and glomerulonephritis can be seen in mice on 
a C57BL/6 genetic background25.  
In order to study the simultaneous effects of atherosclerosis in lupus, gld-/- 
mice are crossed with ApoE deficient mice, which are discussed above, to yield 
gld.apoE-/- mice. gld.apoE-/- mice have more severe autoimmunity than mice with 
the gld mutation alone and more severe atherosclerosis than mice with apoE 
deficiency alone32.   
ii) gld.apoE.Irf5 -/- mice 
These gld.apoE-/- mice were further backcrossed with Irf5-/- mice. 
gld.apoE-/-.Irf5-/- mice were crossed with gld.apoE+/+ mice to generate gld.apoE-/-
.Irf5+/- mice. Experimental mice were obtained by breeding Irf5 heterozygous 
gld.apoE-/- mice to obtain Irf5+/+, Irf5+/- and Irf5-/- gld.apoE-/- littermates. 
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Results 
 In our bone marrow chimeras we set out to characterize the macrophages 
and quantify the activity within the atherosclerotic lesions. Unfortunately, we 
found that the F4/80 could not be localized to the cell surface within the lesion. 
Instead, the core of the lesion was colored with what appeared to be a mass of 
non-specific staining. This result suggests that either the macrophages were in 
the process of differentiating into foam cells and thus losing their F4/80 
expression, or the macrophages were undergoing apoptosis as foam cells and 
thus scattering the cell surface-specific F4/80 throughout the core of the 
atherosclerotic lesion. The latter theory is supported by the fact that the 
hematoxylin stain was also unable to clearly delineate cell borders. 
 An interesting finding, however, is the consistent appearance of 
macrophages on the surface of the leaflets, inter-leaflet triangles, as well as in 
the tunica intima. As we have seen with our time-course project, macrophages 
appear in these areas very early after Western diet is started and they continue 
to be present even after lesion formation. The following shows the results of the 
F4/80 staining in respect to the macrophage accumulation on the leaflets and 
tunica intima. Sections were analyzed by grading the prevalence of the positive 
stain on a score of 0-3. A score of “0” meant very little or no positive staining was 
found, a score of “1” indicated that distinct macrophages could be seen but their 
presence was not pervasive. A score of “3” was awarded when the staining was 
diffuse throughout the region of the tissue. Scores within an experimental group 
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were added together and averaged by the number of mice in the group to 
achieve a “macrophage severity score.” (Figure 4)  
 First, we examined the control group of “+/+  +/+”, which is our group of 
gld.ApoE-/- mice that had both Irf5 sufficient donors and recipients. From a 
previous study, these mice are shown to be unprotected from lupus disease but 
have less severe atherosclerosis compared to their Irf5 deficient counterparts. 
We would expect this group to have the least severe atherosclerosis, and 
consequently, the least severe inflammation and macrophage infiltration. 
 Next, we looked at the “-/-  -/-“ group, which is our group of mice who are 
completely deficient in Irf5, having the gene knocked out in both the donor and 
recipient mice. This group is expected to be protected from lupus disease, but 
also expected to have the worst atherosclerosis.  
 In our “+/+  -/-“ group, the donor mouse is Irf5 sufficient, while the 
recipient mouse is irradiated and reconstituted with the donor’s bone marrow. 
This means that the recipient mouse has bone-marrow derived Irf5. Irf5 is 
expected to be most highly expressed in hematopoietic cell lineages, such as 
monocytes, macrophages, B lymphocytes and dendritic cells. Therefore, we 
would expect to have a result closer to a completely Irf5 sufficient mouse. 
However, since it is still missing Irf5 from non-bone marrow cells, we would 
expect to see some more inflammation and macrophage infiltration compared to 
the “+/+  +/+” group. 
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 Finally, in our “-/-  +/+” group, the donor mouse is Irf5 deficient and our 
recipient mouse will only have Irf5 derived from peripheral, non-hematopoietic 
tissues such as muscle and liver. This phenotype should be closer to that of the 
completely Irf5 deficient mouse, since it was expected that only a small fraction 
of Irf5 was expressed in non-bone marrow cells. However, with some Irf5 
expression, we should expect to see less inflammation and macrophage 
infiltration compared to the “-/-  -/-“ group. 
 Our results did not provide conclusive evidence that If5 played a large role 
in macrophage severity. Macrophage severity scores of the leaflets varied from 1 
to 1.5, but did not correlate with the amount of expected Irf5 expression. No 
difference was seen between mice with complete Irf5 sufficiency and mice with 
complete Irf5 deficiency, with both groups scoring 1.286, despite the fact that 
these two groups would be expected to show the greatest contrast in phenotype. 
Irf5+/+ donors to Irf5-/- recipients showed the highest score of 1.5, and Irf5-/- 
donors to Irf5+/+ recipients showed the lowest score of 1. This may be due to the 
fact that these groups have fewer n and may be more influenced by outlier data. 
 In the tunica adventitia, macrophage score seems to correlate with Irf5 
expression in the first three groups shown (+/++/+, +/+-/-, -/- +/+). 
However, the group with complete Irf5 deficiency scored the highest in 
macrophage severity and thus suggests that the two are not correlated. 
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Figure 4. Macrophage severity score, calculated by giving each mouse a score from 0-2 and 
averaging by the number of mice in that category. A score of “0” indicates no convincing 
macrophage staining. A score of “1” indicates visible macrophage F4/80 staining in a scattered 
pattern. A score of “2” indicates diffuse or intense F/80 staining. Please see Figure 5 for 
representative photos of each scoring. 
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Figure 5. Representative images of the scoring system used in Figure 4. Green arrows indicate 
areas that would be most likely to have macrophages but do not have any positive staining. 
Yellow arrows indicate areas of positive macrophage staining. 
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Discussion 
 No strong relations were seen between the degree of macrophage 
accumulation in the aortic root and the amount of Irf5 expression in our bone 
marrow chimera gld.apoE-/- mice. Macrophage severity scores of the leaflet and 
the tunica adventitia also did not seem to affect one another. Macrophage 
infiltration did not have an obviously apparent relationship to atherosclerotic 
lesion size, though this analysis was not quantitatively done due to the lack of an 
antibody marker that could delineate the cells within the atherosclerotic plaque. 
Thus, more work should be done to characterize macrophages in the lesion in 
order to quantify disease severity and its relationship to macrophage 
accumulation. 
CONCLUSION AND FUTURE DIRECTIONS 
 Unfortunately, our findings do not suggest a strong role of Irf5 in 
macrophage infiltration in the pathogenesis of CVD in lupus mouse models. 
However, our data does not disprove the possibility that macrophages have a 
large impact on lesion formation as foam cells or other monocyte-like cells. The 
next step to further understand the pathogenesis of atherosclerosis in lupus 
mouse models may be to characterize the macrophages with other markers such 
as Mac3. It is also of interest to quantify other inflammatory cells and mediators, 
such as B and T lymphocytes and dendritic cells. 
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 Our data do have findings of interest however, as the F4/80 macrophage 
staining was consistently seen aortic leaflets of mice of different genotypes, 
sexes, ages, and times of exposure to Western diet. The exact mechanism of 
migration or perhaps the migratory pathway of the macrophage is of great 
interest, and could shed light on the macrophages’ means of travelling to the 
necrotic core. This consistent finding of macrophage accumulation on aortic 
leaflets could also be a characteristic of lupus-mediated inflammation of the 
heart, known as Libman-Sacks endocarditis. This is an exciting result found in 
the mouse aortic root, which provides the opportunity to be studied as a new 
Libman-Sacks endocarditis mouse model.  
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